Study size and documentation to detect injection-related hepatitis C in prison

Area of Science:

• Public Health
• Epidemiology
• Infectious Diseases

Background:

• Hepatitis C virus (HCV) remains a significant public health concern, particularly within correctional facilities.
• Injection drug use is a primary driver of HCV transmission, and prison environments present unique challenges for control.
• Understanding transmission dynamics in prisons is essential for developing effective prevention strategies.

Purpose of the Study:

• To estimate the required study size to detect injection-related hepatitis C transmission in UK prisons.
• To assess the statistical power of different study designs for identifying HCV seroconversions in incarcerated populations.
• To inform the design of future research aimed at quantifying HCV transmission risks within prisons.

Main Methods:

• Utilized existing data on HCV prevalence, injection-related transmission, and needle use in prisons.
• Incorporated new data on HCV infectiousness to model study power.
• Calculated the probability of detecting seroconversions in pilot (500 prisoners, 10 weeks) and definitive (3000 prisoners, 10 weeks) study scenarios.

Main Results:

• A pilot study of 500 prisoners over 10 weeks has a 65% chance of detecting seroconversion under conservative assumptions (1 injection/week, 3% transmission rate).
• Higher transmission rates (e.g., 10%) significantly increase the statistical power of such studies.
• A definitive study of 3000 prisoners for 10 weeks is expected to detect approximately six seroconversions, even with conservative estimates.

Conclusions:

• Adequate study design and statistical power are critical to accurately assess hepatitis C transmission in prisons.
• False-negative findings can lead to complacency and hinder effective public health interventions.
• Future studies should document six key risk-factor themes to provide a comprehensive understanding of HCV transmission dynamics.